Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells

  • San Miguel J
  • Paiva B
  • Lasarte J
  • 28


    Mendeley users who have this article in their library.
  • 4


    Citations of this article.


NY-ESO-1 TCR-engineered T cells have shown activity in solid tumors. Recent work supports their use in multiple myeloma by showing that ex vivo antigen-specific expanded T cells traffic to and persist in bone marrow, are well tolerated, and produce promising response rates when infused after stem cell transplantation.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Jesus F. San Miguel

  • Bruno Paiva

  • Juan Jose Lasarte

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free